Estimating the response and economic burden of rheumatoid arthritis patients treated with biologic disease-modifying antirheumatic drugs in Taiwan using the National Health Insurance Research Database (NHIRD).
BACKGROUND:Previous studies in Taiwan utilizing the Taiwan's National Health Insurance Database (NHIRD) have estimated the direct healthcare costs of RA patients, but they have not focused on patients on bDMARDs, or considered patients' response to therapy. OBJECTIVES:The objective of this...
Main Authors: | Qiang Shi, Ko-Jen Li, Tamas Treuer, Bruce C M Wang, Carol L Gaich, Chien-Hsun Lee, Wen-Shuo Wu, Wesley Furnback, Chao-Hsiun Tang |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2018-01-01
|
Series: | PLoS ONE |
Online Access: | https://doi.org/10.1371/journal.pone.0193489 |
Similar Items
-
Data resource profile: the National Health Insurance Research Database (NHIRD)
by: Liang-yu Lin, et al.
Published: (2018-12-01) -
Switching and Discontinuation Pattern of Biologic Disease-Modifying Antirheumatic Drugs and Tofacitinib for Patients With Rheumatoid Arthritis in Taiwan
by: Ko-Jen Li, et al.
Published: (2021-07-01) -
Designing and Pricing Commercial Stroke Insurance – An Application of Taiwan NHIRD
by: Jiengwuen Cai, et al.
Published: (2015) -
Antirheumatic treatment is associated with reduced serum Syndecan-1 in Rheumatoid Arthritis.
by: Gia Deyab, et al.
Published: (2021-01-01) -
Genetic Polymorphisms Associated with Rheumatoid Arthritis Development and Antirheumatic Therapy Response
by: Dmitry S. Mikhaylenko, et al.
Published: (2020-07-01)